Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study

In a post hoc analysis of 2,233 patients with myelofibrosis from the phase 3b JUMP trial, 52.9% developed new-onset or worsening anemia within 12 weeks of ruxolitinib initiation. Ruxolitinib improved spleen size and symptoms regardless of baseline anemia status or development of treatment-related anemia, with no differences in spleen response or overall survival between subgroups. The researchers concluded that these findings support the use of ruxolitinib in patients with myelofibrosis irrespective of anemia status.